| 1 |
孙宁玲，霍勇，王继光，等．难治性高血压诊断治疗中国专家共识[J]．中国医学前沿杂志.2013, 5(6): 5-10.
|
| 2 |
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research [J]. Hypertension, 2008, 51(6): 1403-1419.
|
| 3 |
Persel SD. Prevalence of resistant hypertension in the United States, 2003- 2008 [J]. Hypertension, 2011, 57(6): 1076-1080.
|
| 4 |
De la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring [J]. Hypertension, 2011, 57(5): 898-902.
|
| 5 |
Ma W, Zhang Y, HOT- CHINA working group. Low rate of resistant hypertension in Chinese patients with hypertension-an analysis of the HOT- CHINA study [J]. J Hypertens, 2013, 31(12): 2386-2390.
|
| 6 |
Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients [J]. Circulation, 2012, 125 (13): 1635-1642.
|
| 7 |
Kalaitzidis R, Li SY, Wang CC, et al. Hypertension in early- stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP) [J]. Am J Kidney Dis, 2009, 53(4 Suppl 4): S22-S31.
|
| 8 |
Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease [J]. Am J Kidney Dis, 1998, 32(5 Suppl 3): S120-S141.
|
| 9 |
Tanner RM. Prevalence of apparent treatment- resistant hypertension among individuals with CKD [J]. Clin J Am Soc Nephrol, 2013, 8(9): 1583-1590.
|
| 10 |
Feldman RD, Brass EP. From bad behaviour to bad biology: pitfalls and promises in the management of resistant hypertension [J]. Can J Cardiol, 2013, 29 (5): 549-556.
|
| 11 |
Shimbo D, Levitan EB, Booth JN, et al. The contribution of unhealthy lifestyle factors to apparent resistant hypertension: findings from the reasons for geographic and racial differences in stroke (REGARDS) study [J]. J Hypertens, 2013, 31(2): 370-376.
|
| 12 |
Schirpenbach C, Reincke M. Epidemiology and etiology of therapy- resistant hypertension [J]. Internist (Berl), 2009, 50 (1): 7-16.
|
| 13 |
Viera AJ. Resistant hypertension [J]. J Am Board Fam Med, 2012, 25 (4): 487-495.
|
| 14 |
Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnea and aldosterone [J]. J Hum Hypertens, 2012, 26 (5): 281-287.
|
| 15 |
Orth SR, Amann K, Strojek K, et al. Sympathetic overactivity and arterial hypertension in renal failure [J]. Nephrol Dial Transplant, 2001, 16(Suppl 1): 67-69.
|
| 16 |
Phillips JK. Pathogenesis of hypertension in renal failure: Role of the sympathetic nervous system and renal afferents [J]. Clin Exp Pharmacol Physiol, 2005, 32(5- 6): 415-418.
|
| 17 |
Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L- arginine paradox" and acts as a novel cardiovascular risk factor [J]. J Nutr, 2004, 134(10 Suppl): 2842S-2847S.
|
| 18 |
Lariviere R, Lebel M. Endothelin- 1 in chronic renal failure and hypertension [J]. Can J Physiol Pharmacol, 2003, 81(6): 607-621.
|
| 19 |
Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin Ⅱ, and hypertension [J]. Semin Nephrol, 2004, 24(4): 366-378.
|
| 20 |
Kincaid SP. Hypothesis: obesity and the insulin resistance syndrome play a major role in end- stage renal failure attributed to hypertension and labelled "hypertensive nephrosclerosis" [J]. J Hypertens, 2004, 22(6): 1051-1055.
|
| 21 |
夏运风，甘华．尿毒症难治性高血压的发生机制[J]．山西医科大学学报，2002，33(5): 479-481.
|
| 22 |
Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. a scientific statement from the American Heart Association professional education committee of the council for high blood pressure research [J]. Hypertension, 2008, 51(6): 1403-1419.
|
| 23 |
Hanselin MR, Saseen JJ, Alen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents [J]. Hypertension, 2011, 58(6): 1008-1013.
|
| 24 |
第八届中华肾脏病学会慢性肾脏病高血压治疗专家协作组．α/β受体阻断剂在慢性肾脏病高血压治疗中的实践指南[J]．中华医学杂志，2013，93(48): 3812-3816.
|
| 25 |
Di Bona GF. Translational medicine: the antihypertensive effect of renal denervation [J]. Am J Physiol Regul Integr Comp Physiol, 2010, 298(2): R245-R253.
|
| 26 |
Symplicity HTN- 1 Investigators. Catheter- based renal sympathetic denervation d for resistant hypertension: durability of blood pressure reduction out to 24 months [J]. Hypertension, 2011, 57(5): 911-917.
|
| 27 |
Esler MD. Renal sympathetic denervation for treatment of drug resistant hypertension: one- year results from the symplicity HTN- 2 randomized, controlled trial [J]. Circulation, 2012, 126(25): 2976-2982.
|
| 28 |
陈枫，黄云剑，李玉英，等．不同血液净化方案对尿毒症难治性高血压的疗效观察[J]．重庆医学，2007，36(3): 426-427.
|
| 29 |
肖嘉．高通量血液透析治疗难治性高血压患者的临床效果[J]．透析与人工器官，2013，24(1): 1-4.
|
| 30 |
Scheffers JJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European Multicenter feasibility study [J]. J Am Col Cardiol, 2010, 56(15): 1254-1258.
|
| 31 |
Ng MM1, Sica DA, Frishman WH. Rheos: an implantable carotid sinus stimulation device for the nonpharmacologic treatment of resistant hypertension [J]. Cardiol Rev, 2011, 19(2): 52-57.
|